TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 Antimicrobial Resistance Threats Report identifies 19 pathogens across three threat levels and estimates they cause 9.7 million infections and 50,800 deaths annually. Four drug-resistant pathogens are classified as urgent threats; the report also adds six organisms to a watch list and downgrades C. difficile from urgent to serious.
The CDC’s 2026 Antimicrobial Resistance Threats Report lists 19 pathogens as concerning, serious or urgent and estimates that the organisms cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens received the agency’s highest threat classification, while six others were added to a watch list of potential threats.
The four drug-resistant pathogens designated urgent threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The CDC says urgent threats require aggressive action. The report describes C. auris as a multidrug-resistant yeast that can cause severe infections, especially among people already seriously ill. Reported U.S. cases rose from 48 in 2016 to 4,523 in 2023.
The report also gives 2023 estimates for two resistant bacteria. Carbapenem-resistant Acinetobacter was associated with 9,497 U.S. hospitalizations and an estimated 817 deaths that year; 63% of cases began outside hospitals. Carbapenem-resistant Enterobacterales, which include some E. coli and Klebsiella strains, were associated with 14,878 hospitalizations and an estimated 1,252 deaths. The CDC says people with ventilators or catheters and those receiving longer antibiotic courses face greater risk.
Drug-resistant N. gonorrhoeae was estimated to cause 787,000 U.S. infections in 2023. The report says 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or showed elevated minimum inhibitory concentrations. The CDC also elevated drug-resistant N. meningitidis to serious-threat status and added drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria to its watch list.
Risks for Patients and Care
Antimicrobial resistance can make infections harder to treat and can affect care beyond the infection itself. Wendy Armstrong, president of the Infectious Diseases Society of America, said resistant infections can prolong hospital stays and increase health care costs. She also warned that they can make treatments such as chemotherapy, organ transplants and surgery more difficult or, in some cases, impossible to provide safely.
The figures combine a wide range of pathogens and threat categories, rather than describing one outbreak or a single group of patients. The urgent classification signals the CDC’s assessment of particularly serious threats, but the report’s separate pathogen estimates show why hospitals, public health agencies and clinicians need to track specific organisms and resistance patterns.
For readers, the findings are a public health warning, not an individual prediction of risk. Several highlighted infections disproportionately affect people receiving hospital or nursing-home care, while gonorrhea is a sexually transmitted infection. The report’s estimates do not mean every infection is resistant or that treatment will fail; they point to the scale of infections and deaths attributed to the pathogens included.
Products Worth Considering
Levoit Vital 100S-P Air Purifier for Home and Pets
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
Levoit Core 300S-P Smart Wi-Fi Air Purifier
As an affiliate, we earn on qualifying purchases.
How the Threat List Changed
The CDC’s report groups pathogens by assessed threat level and also identifies organisms on a watch list. The 2026 update includes 19 pathogens across concerning, serious and urgent categories, as well as six watch-list organisms described as potential threats. The source report does not provide a single year-by-year comparison for the combined estimate of 9.7 million infections and 50,800 deaths, so that total should be read as the agency’s current estimate, not as a measured annual increase.
One change is a lower classification for Clostridioides difficile, which moved from urgent to serious. The CDC attributed the change in part to successful infection-prevention measures and a decline in cases since 2011. The move does not mean C. difficile is no longer a serious concern; it reflects a revised assessment of its threat level.
The report also notes developments in treatment. The U.S. Food and Drug Administration approved gepotidacin, marketed as Blujepa, and zoliflodacin, marketed as Nuzolvence, the previous year as new antibiotics for gonorrhea. The source describes them as the first new antibiotics for gonorrhea in decades. Their approval comes as the CDC continues to track drug resistance in the infection.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Estimates
The source report gives an annual combined estimate for the pathogens but does not specify in the supplied material the exact estimation period, methods or uncertainty ranges behind the 9.7 million infections and 50,800 deaths. It also does not break down that total by each threat category, so the figures should not be attributed solely to the four urgent pathogens.
Several figures cited for individual pathogens are specifically for 2023, while the report itself is dated 2026. The supplied information does not explain how much those estimates have changed since then. The six watch-list organisms are described as potential threats with uncertain disease burden; their listing is not confirmation that they currently cause a known number of infections or deaths.
Policy and Surveillance Ahead
The CDC’s updated classifications give public health officials and health care systems a current framework for monitoring resistant infections and directing prevention efforts. The source material does not identify a specific new federal response or implementation timetable tied to publication of the report.
Armstrong called for passage of the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs against threatening pathogens and infections. According to the source report, versions of the bill remain stalled in congressional committees. Their next legislative steps, and whether Congress will act, are not specified.
Further reporting and updated surveillance will be needed to show how the newly classified pathogens’ disease burden changes, whether prevention measures continue to reduce C. difficile cases, and how newly approved gonorrhea antibiotics perform as resistance patterns are monitored. The CDC report sets out current classifications and estimates; it does not resolve those future questions.
Key Questions
What does the CDC estimate these pathogens cause each year?
The report estimates that the pathogens across its threat categories cause 9.7 million infections and 50,800 deaths annually in the United States. The supplied material does not specify the exact estimation period or provide uncertainty ranges.
Which pathogens are classified as urgent threats?
The four urgent drug-resistant threats named in the report are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to the serious category?
The CDC says C. difficile moved from urgent to serious, in part because infection-prevention measures have helped reduce case numbers since 2011. It remains classified as a serious threat.
What is on the CDC’s watch list?
The report adds six potential threats to a watch list. The supplied material names drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria; it does not identify the other three in the information provided. The listed organisms have an uncertain disease burden and are not presented as confirmed causes of a specific number of cases.
What is the PASTEUR Act?
It is proposed federal legislation that, according to the Infectious Diseases Society of America’s president, would create a program to develop antimicrobial drugs against threatening pathogens and infections. The source report says versions of the bill remain stalled in congressional committees.
Source: medpagetoday.com
